• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本患者滤泡性甲状腺癌中PAX8-PPARγ重排的低频率

Low frequency of PAX8-PPARγ rearrangement in follicular thyroid carcinomas in Japanese patients.

作者信息

Mochizuki Kunio, Kondo Tetsuo, Oishi Naoki, Tahara Ippei, Inoue Tomohiro, Kasai Kazunari, Nakazawa Tadao, Okamoto Takahiro, Shibata Noriyuki, Katoh Ryohei

机构信息

Department of Pathology, University of Yamanashi, Yamanashi, Japan.

出版信息

Pathol Int. 2015 May;65(5):250-3. doi: 10.1111/pin.12270. Epub 2015 Feb 23.

DOI:10.1111/pin.12270
PMID:25708358
Abstract

Paired-box gene 8 (PAX8)-peroxisome proliferator-activated receptor-γ (PPARγ) gene fusion has been identified at significant frequency in follicular thyroid carcinomas (FTCs) with cytogenetically detectable translocation t(2;3)(q13;p25). This represents a possible specific molecular marker for follicular carcinoma. In this study, we examined PAX8-PPARγ rearrangement in 24 FTC samples from Japanese patients by reverse transcribed-polymerase chain reaction (RT-PCR) using two upstream PAX8 primers located in exons 7 and 8 and a downstream primer in exon 1 of PPARγ. The fusion gene was detected in only one of 24 FTCs (4%). The FTC with PAX8-PPARγ rearrangement from a 56-year-old man showed a product consistent with fusion between exon 8 of PAX8 and exon 1 of PPARγ. It was confirmed by direct sequencing. This FTC was histologically encapsulated, composed of trabeculae and small follicles and had complete penetration of the capsule by tumor tissues (minimally invasive type). The frequency of the fusion gene in this study was much lower than the 29-63% noted in reports from other countries suggesting that FTCs in Japanese patients may have a special genetic background, and that the high iodine intake from a typical Japanese diet might influence the frequency of the fusion gene in FTCs.

摘要

配对盒基因8(PAX8)-过氧化物酶体增殖物激活受体γ(PPARγ)基因融合在细胞遗传学上可检测到易位t(2;3)(q13;p25)的滤泡状甲状腺癌(FTC)中以显著频率被发现。这代表了滤泡状癌一种可能的特异性分子标志物。在本研究中,我们通过逆转录-聚合酶链反应(RT-PCR),使用位于PAX8外显子7和8的两条上游引物以及PPARγ外显子1中的一条下游引物,检测了24例来自日本患者的FTC样本中的PAX8-PPARγ重排情况。在24例FTC中仅1例(4%)检测到融合基因。来自一名56岁男性的具有PAX8-PPARγ重排的FTC显示出与PAX8外显子8和PPARγ外显子1之间融合一致的产物。通过直接测序得以证实。该FTC在组织学上有包膜,由小梁和小滤泡组成,肿瘤组织完全穿透包膜(微侵袭型)。本研究中融合基因的频率远低于其他国家报告中指出的29%-63%,这表明日本患者的FTC可能具有特殊的遗传背景,并且典型日本饮食中的高碘摄入可能会影响FTC中融合基因的频率。

相似文献

1
Low frequency of PAX8-PPARγ rearrangement in follicular thyroid carcinomas in Japanese patients.日本患者滤泡性甲状腺癌中PAX8-PPARγ重排的低频率
Pathol Int. 2015 May;65(5):250-3. doi: 10.1111/pin.12270. Epub 2015 Feb 23.
2
PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma.甲状腺结节中的PAX8/PPARγ重排可预测滤泡型癌,尤其是乳头状癌的包膜型滤泡变体。
Thyroid. 2014 Sep;24(9):1369-74. doi: 10.1089/thy.2014.0067. Epub 2014 Jul 16.
3
Is thyroid follicular cancer in Japanese caused by a specific t(2; 3)(q13; p25) translocation generating Pax8-PPAR gamma fusion mRNA?日本的甲状腺滤泡癌是由产生Pax8-PPARγ融合mRNA的特定t(2;3)(q13;p25)易位所致吗?
Endocr J. 2004 Jun;51(3):361-6. doi: 10.1507/endocrj.51.361.
4
Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.在一个自主功能性滤泡性甲状腺癌患者中,发现了一个配对盒基因 8-过氧化物酶体增殖物激活受体 γ(PAX8-PPARγ)重排嵌合体,该患者的 TSH 受体存在激活突变。
Endocr Relat Cancer. 2010 Jun 3;17(3):599-610. doi: 10.1677/ERC-09-0069. Print 2010 Sep.
5
Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations.具有PAX8-PPARγ1重排的滤泡性甲状腺肿瘤表现出特征性的基因改变。
Am J Pathol. 2005 Jul;167(1):223-31. doi: 10.1016/s0002-9440(10)62967-7.
6
PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.PAX8-PPARγ重排在甲状腺乳头状癌滤泡变体中经常被检测到。
J Clin Endocrinol Metab. 2006 Jan;91(1):213-20. doi: 10.1210/jc.2005-1336. Epub 2005 Oct 11.
7
PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues.PAX8和过氧化物酶体增殖物激活受体γ1基因在甲状腺良恶性组织中的表达状态
Eur J Endocrinol. 2004 Sep;151(3):367-74. doi: 10.1530/eje.0.1510367.
8
Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases.甲状腺癌中 PAX8-PPARγ 易位的诊断和预后意义——一项基于 TMA 的 226 例研究。
Histopathology. 2013 Aug;63(2):234-41. doi: 10.1111/his.12150. Epub 2013 Jun 6.
9
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.PAX8-PPARG 易位甲状腺滤泡癌中基因表达的描绘、功能验证及生物信息学评估
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1983-93. doi: 10.1158/1078-0432.CCR-05-2039.
10
Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings.韩国人群滤泡源性甲状腺肿瘤中 RAS 突变和 PAX8/PPARγ 重排的分析:频率及超声表现。
J Endocrinol Invest. 2015 Aug;38(8):849-57. doi: 10.1007/s40618-015-0311-x. Epub 2015 May 22.

引用本文的文献

1
Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review.亚洲与西方国家滤泡状甲状腺癌的基因差异:一项系统评价
Gland Surg. 2020 Oct;9(5):1813-1826. doi: 10.21037/gs-20-356.
2
Mutation profiles of follicular thyroid tumors by targeted sequencing.通过靶向测序分析滤泡性甲状腺肿瘤的突变谱。
Diagn Pathol. 2019 May 10;14(1):39. doi: 10.1186/s13000-019-0817-1.
3
Refractory thyroid carcinoma: which systemic treatment to use?难治性甲状腺癌:应采用哪种全身治疗?
Ther Adv Med Oncol. 2018 Jan 23;10:1758834017752853. doi: 10.1177/1758834017752853. eCollection 2018.
4
Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma.甲状腺滤泡性腺瘤的突变负荷和进化年龄与滤泡性癌相当。
Oncotarget. 2016 Oct 25;7(43):69638-69648. doi: 10.18632/oncotarget.11922.